Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2024 Jul 2

PMID 38953306

Authors

Guangman Cui

Shaohui Deng

Biao Zhang

Manchun Wang

Zhousheng Lin

Xinyue Lan

Zelong Li

Guangyu Yao

Meng Yu

Jun Yan

Affiliations

Soon will be listed here.

Abstract

The extracellular matrix (ECM) is critical for drug resistance in colorectal cancer (CRC). The abundant collagen within the ECM significantly influences tumor progression and matrix-mediated drug resistance (MMDR) by binding to discoidin domain receptor 1 (DDR1), but the specific mechanisms by which tumor cells modulate ECM via DDR1 and ultimately regulate TME remain poorly understand. Furthermore, overcoming drug resistance by modulating the tumor ECM remains a challenge in CRC treatment. In this study, a novel mechanism is elucidated by which DDR1 mediates the interactions between tumor cells and collagen, enhances collagen barriers, inhibits immune infiltration, promotes drug efflux, and leads to MMDR in CRC. To address this issue, a multistage drug delivery system carrying DDR1-siRNA and chemotherapeutic agents is employed to disrupt collagen barriers by silencing DDR1 in tumor, enhancing chemotherapy drugs diffusion and facilitating immune infiltration. These findings not only revealed a novel role for collagen-rich matrix mediated by DDR1 in tumor resistance, but also introduced a promising CRC treatment strategy.

Citing Articles

Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy.

Cui G, Deng S, Zhang B, Wang M, Lin Z, Lan X Adv Sci (Weinh). 2024; 11(33):e2402107.

PMID: 38953306 PMC: 11434232. DOI: 10.1002/advs.202402107.

References

Chen D, Chen H, Chi L, Fu M, Wang G, Wu Z . Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer. JAMA Netw Open. 2021; 4(11):e2136388. PMC: 8634059. DOI: 10.1001/jamanetworkopen.2021.36388. View

Rix U, Hantschel O, Durnberger G, Remsing Rix L, Planyavsky M, Fernbach N . Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12):4055-63. DOI: 10.1182/blood-2007-07-102061. View

Shen Y, Wang X, Lu J, Salfenmoser M, Wirsik N, Schleussner N . Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer. Cancer Cell. 2020; 37(6):800-817.e7. DOI: 10.1016/j.ccell.2020.05.005. View

Sahin U, Blobel C . Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett. 2006; 581(1):41-4. DOI: 10.1016/j.febslet.2006.11.074. View

Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M . Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6(12):815-23. DOI: 10.1038/nnano.2011.166. View

Kalluri R . The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9):582-98. DOI: 10.1038/nrc.2016.73. View

Xin Y, Huang M, Guo W, Huang Q, Zhang L, Jiang G . Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017; 16(1):134. PMC: 5534073. DOI: 10.1186/s12943-017-0683-y. View

Bent E, Millan-Barea L, Zhuang I, Goulet D, Frose J, Hemann M . Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun. 2021; 12(1):6218. PMC: 8553783. DOI: 10.1038/s41467-021-26407-4. View

Narra K, Mullins S, Lee H, Strzemkowski-Brun B, Magalong K, Christiansen V . Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007; 6(11):1691-9. DOI: 10.4161/cbt.6.11.4874. View

10.

Sommer A, Kordowski F, Buch J, Maretzky T, Evers A, Andra J . Phosphatidylserine exposure is required for ADAM17 sheddase function. Nat Commun. 2016; 7:11523. PMC: 4866515. DOI: 10.1038/ncomms11523. View

11.

Cui G, Deng S, Zhang B, Wang M, Lin Z, Lan X . Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy. Adv Sci (Weinh). 2024; 11(33):e2402107. PMC: 11434232. DOI: 10.1002/advs.202402107. View

12.

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

13.

Ohta Y, Fujii M, Takahashi S, Takano A, Nanki K, Matano M . Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022; 608(7924):784-794. DOI: 10.1038/s41586-022-05043-y. View

14.

Cukierman E, Pankov R, Stevens D, Yamada K . Taking cell-matrix adhesions to the third dimension. Science. 2001; 294(5547):1708-12. DOI: 10.1126/science.1064829. View

15.

Su Z, Dong S, Zhao S, Liu K, Tan Y, Jiang X . Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat. 2021; 58:100777. DOI: 10.1016/j.drup.2021.100777. View

16.

Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H . Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022; 15(1):34. PMC: 8943941. DOI: 10.1186/s13045-022-01252-0. View

17.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J . Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-4. PMC: 3711467. DOI: 10.1038/nature11183. View

18.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

19.

Veit M, Koyro K, Ahrens B, Bleibaum F, Munz M, Rovekamp H . Anoctamin-6 regulates ADAM sheddase function. Biochim Biophys Acta Mol Cell Res. 2018; 1865(11 Pt A):1598-1610. DOI: 10.1016/j.bbamcr.2018.08.011. View

20.

Chen D, Chen G, Jiang W, Fu M, Liu W, Sui J . Association of the Collagen Signature in the Tumor Microenvironment With Lymph Node Metastasis in Early Gastric Cancer. JAMA Surg. 2019; 154(3):e185249. PMC: 6439641. DOI: 10.1001/jamasurg.2018.5249. View